|
Fatty acid measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association meta-analysis of circulating odd-numbered chain saturated fatty acids: Results from the CHARGE Consortium.
|
29738550 |
2018 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Here we report that NRBF2 (nuclear receptor binding factor 2), a key component and regulator of the PtdIns3K, is involved in APP-CTFs homeostasis in AD cell models.
|
28980867 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Intriguingly, Alzheimer's disease (AD)-associated pathological proteins, such as BACE-1, APP, β-CTF, α-CTF, Aβ <sub>1-42</sub> and phosphorylated tau proteins (S199, S396, T205, S214 and S404), were substantially increased after BPA exposure, and these effects were abrogated by insulin and rosiglitazone treatment; these findings underscore the specific roles of insulin signaling in BPA-mediated AD-like neurotoxicity.
|
28790390 |
2017 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
In particular, it affects the production of β-CTF which is increasingly considered to be an important mediator in AD independent of Aβ.
|
27430330 |
2016 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
The AAV1-I(2NTF-CTF) rats not only offer a disease-relevant model of the sporadic form of Alzheimer's disease but also represent a practical and widely available animal model.
|
23948903 |
2013 |
|
Alzheimer's Disease
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Processing of β-CTF by γ-secretase releases amyloid-β (Aβ), which is assumed to cause AD.
|
22170863 |
2012 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
The amyloid-β (Aβ) peptide is contained within the C-terminal fragment (β-CTF) of the amyloid precursor protein (APP) and is intimately linked to Alzheimer's disease.
|
21186781 |
2011 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
We recently reported a correlation between proteolytic product of gelsolin (carboxyl-terminal fragment of gelsolin, gelsolin-CTF) and severity of Alzheimer's disease.
|
20847428 |
2010 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize observations indicating that both CTF and Abeta may participate in the neuronal degeneration in the progress of AD by differential mechanisms.
|
15821343 |
2005 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Overexpression of TWIST1 and NY-ESO1 mRNA was observed in 42% and 39.5% (P ˂ 0.05) of tumors, respectively.
|
31158427 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
And, increased ESCO1 expression was significantly associated with higher grade (P < 0.001), higher tumor stage (P = 0.014), and multifocality (P = 0.042).
|
26547586 |
2016 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Despite the identification of the epigenetical silencing of the NY-ESO1 gene in a large variety of tumors, the molecular mechanism involved in this phenomenon is not fully elucidated.
|
23312906 |
2013 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
This system contains multimerized E2F-responsive elements in combination with the binding sites for ubiquitous transcription factors Sp1 and CTF/NF1. pESM6 could drive a high-level transgene expression comparable to that of the CMV IE promoter and exert constitutive activity in cells expressing DNA tumor viral oncogenes.
|
16461008 |
2006 |
|
Amyloidosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
AβPP-CTF, Aβ45, and aggregated Aβ colocalized most strongly with mitochondria and endosomes and less with lysosomes and autophagosomes.Differences in iAβ by sex were minor.
|
31771065 |
2020 |
|
Down Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
The release of APP-CTFs-enriched exosomes may have a pathogenic role by transporting APP-CTFs into naïve neurons and propagating these neurotoxic metabolites, which are also a source of amyloid β, throughout the brain, but also provides a benefit to DS neurons by shedding APP-CTFs accumulated intracellularly.
|
31479861 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
We aimed in this study to analyze the correlation between NY-ESO1 and TWIST1 in esophageal squamous cell carcinoma (ESCC), as well as their impact on EMT process.
|
31158427 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Based on our findings, it may be proposed that a vital association is exist between the EMT and the acquisition of cancer stemness state in tumor cells through the TWIST1/NY-ESO1 axis and it can be a critical hallmark in ESCC tumorigenesis.
|
31158427 |
2019 |
|
Complete Trisomy 21 Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
The release of APP-CTFs-enriched exosomes may have a pathogenic role by transporting APP-CTFs into naïve neurons and propagating these neurotoxic metabolites, which are also a source of amyloid β, throughout the brain, but also provides a benefit to DS neurons by shedding APP-CTFs accumulated intracellularly.
|
31479861 |
2019 |
|
Amyloidosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In particular, it affects the production of β-CTF which is increasingly considered to be an important mediator in AD independent of Aβ.
|
27430330 |
2016 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
There is increasing evidence suggesting that establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) was involved in tumorigenesis.
|
26547586 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
The overexpression of LAGE1, MAGE-A4 and NY-ESO1 was found in 39, 90.2 and 41.4% of ESCC samples respectively.
|
21613820 |
2011 |
|
Down Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gelsolin-CTF was not observed in frontal cortex of young DS (age 0.5-23 years) and age-matched control subjects.
|
20847428 |
2010 |
|
Complete Trisomy 21 Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gelsolin-CTF was not observed in frontal cortex of young DS (age 0.5-23 years) and age-matched control subjects.
|
20847428 |
2010 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
CADM1 α-shedding was induced in AS and DN kidneys and derived from the decrease in full-length CADM1 (FL-CADM1) and increase of the COOH-terminal fragment (α-CTF).
|
29070574 |
2018 |
|
Arterionephrosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CADM1 α-shedding was induced in AS and DN kidneys and derived from the decrease in full-length CADM1 (FL-CADM1) and increase of the COOH-terminal fragment (α-CTF).
|
29070574 |
2018 |